Science Explorer Back to mapMap
Discussion
Company · Osaka · Japan

Ono Pharmaceutical (Japan)

In research, Ono Pharmaceutical (Japan) stands highest in Life Sciences (#6,571 of 11,023 worldwide), Biochemistry, Genetics and Molecular Biology (#3,663 of 5,801 worldwide) and Health Sciences (#11,031 of 16,688 worldwide), over all time.

ono.co.jp/engROR OpenAlex
World rank, 2022-now
#18,634
of 22,385 · #19,975 all time
Rank in Japan
#592
of 924
Research works
894
▼ 31% vs 2018-21
Citations
18k
20.4 per fractional work
Top-10% rate
10.5%
all institutions 10.0%
vs its own fields
1.01×
1.00× is exactly expected
Open access
39%
world 40%
International
18%
world 18%
Ono Pharmaceutical (Japan)

What is Ono Pharmaceutical (Japan) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Life SciencesDomain #6,571 of 11,023 6.4%303
Biochemistry, Genetics and Molecular BiologyField #3,663 of 5,801 6.4%196
Health SciencesDomain #11,031 of 16,688 6.6%369
MedicineField #9,748 of 14,558 6.6%352
Molecular BiologySubfield #2,599 of 3,729 6.5%122
Physical SciencesDomain #16,178 of 17,446 5.0%211

Each strip is that field's whole ranked pool, with the notch where Ono Pharmaceutical (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Ono Pharmaceutical (Japan) work in?

In 2022-now, 50% of research at Ono Pharmaceutical (Japan) is in Health Sciences, 24% in Physical Sciences. Its largest fields are Medicine (48%), Biochemistry, Genetics and Molecular Biology (14%), Chemistry (9%). It does 2.0× the world's share of Health Sciences.

Health Sciences: 36 fractional works · 50.3% of its workMedicine: 35 fractional works · 48.4% of its workOncology: 8 fractional works · 11.5% of its workPulmonary and Respiratory Medicine: 3 fractional works · 4.7% of its workSurgery: 3 fractional works · 3.5% of its workEpidemiology: 2 fractional works · 3.2% of its workPhysiology: 2 fractional works · 2.9% of its workGenetics: 2 fractional works · 2.8% of its workCardiology and Cardiovascular Medicine: 2 fractional works · 2.2% of its workHematology: 1 fractional works · 1.8% of its workPharmacology: 1 fractional works · 1.8% of its workPathology and Forensic Medicine: 1 fractional works · 1.6% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 1.4% of its workRheumatology: 1 fractional works · 1.4% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 1.2% of its workComplementary and alternative medicine: 1 fractional works · 0.9% of its workDermatology: 1 fractional works · 0.9% of its workNeurology: 1 fractional works · 0.8% of its workGeriatrics and Gerontology: 1 fractional works · 0.8% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 0.8% of its workNephrology: 0 fractional works · 0.6% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.6% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.5% of its workOtorhinolaryngology: 0 fractional works · 0.3% of its workImmunology and Allergy: 0 fractional works · 0.3% of its workGastroenterology: 0 fractional works · 0.3% of its workInfectious Diseases: 0 fractional works · 0.3% of its workEmergency Medicine: 0 fractional works · 0.3% of its workOphthalmology: 0 fractional works · 0.2% of its workRehabilitation: 0 fractional works · 0.2% of its workPsychiatry and Mental health: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.3% of its workHealth Professions: 1 fractional works · 1.4% of its workSpeech and Hearing: 0 fractional works · 0.6% of its workHealth Information Management: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.4% of its workNursing: 0 fractional works · 0.3% of its workNutrition and Dietetics: 0 fractional works · 0.3% of its workVeterinary: 0 fractional works · 0.2% of its workPhysical Sciences: 17 fractional works · 24.1% of its workChemistry: 7 fractional works · 9.4% of its workOrganic Chemistry: 6 fractional works · 7.8% of its workPhysical and Theoretical Chemistry: 0 fractional works · 0.6% of its workSpectroscopy: 0 fractional works · 0.5% of its workAnalytical Chemistry: 0 fractional works · 0.3% of its workInorganic Chemistry: 0 fractional works · 0.2% of its workEngineering: 6 fractional works · 7.8% of its workBiomedical Engineering: 2 fractional works · 2.3% of its workControl and Systems Engineering: 1 fractional works · 1.4% of its workCivil and Structural Engineering: 1 fractional works · 1.3% of its workMechanical Engineering: 1 fractional works · 0.9% of its workAutomotive Engineering: 0 fractional works · 0.6% of its workComputational Mechanics: 0 fractional works · 0.4% of its workElectrical and Electronic Engineering: 0 fractional works · 0.2% of its workMechanics of Materials: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.3% of its workComputer Science: 2 fractional works · 2.9% of its workArtificial Intelligence: 1 fractional works · 1.0% of its workComputer Vision and Pattern Recognition: 1 fractional works · 0.7% of its workInformation Systems: 0 fractional works · 0.5% of its workSignal Processing: 0 fractional works · 0.5% of its workComputational Theory and Mathematics: 0 fractional works · 0.3% of its workMathematics: 1 fractional works · 1.7% of its workStatistics and Probability: 1 fractional works · 1.3% of its workApplied Mathematics: 0 fractional works · 0.5% of its workMaterials Science: 1 fractional works · 1.1% of its workMaterials Chemistry: 0 fractional works · 0.6% of its workBiomaterials: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workChemical Engineering: 0 fractional works · 0.6% of its workFluid Flow and Transfer Processes: 0 fractional works · 0.4% of its workCatalysis: 0 fractional works · 0.2% of its workEnvironmental Science: 0 fractional works · 0.3% of its workEarth and Planetary Sciences: 0 fractional works · 0.2% of its workPhysics and Astronomy: 0 fractional works · 0.1% of its workLife Sciences: 17 fractional works · 23.4% of its workBiochemistry, Genetics and Molecular Biology: 10 fractional works · 14.3% of its workMolecular Biology: 8 fractional works · 11.5% of its workCancer Research: 1 fractional works · 1.1% of its workCell Biology: 0 fractional works · 0.6% of its workGenetics: 0 fractional works · 0.6% of its workBiophysics: 0 fractional works · 0.3% of its workMolecular Medicine: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workImmunology and Microbiology: 2 fractional works · 3.5% of its workImmunology: 2 fractional works · 3.4% of its workSmaller subfields together: 0 fractional works · 0.0% of its workPharmacology, Toxicology and Pharmaceutics: 2 fractional works · 2.9% of its workPharmaceutical Science: 2 fractional works · 2.1% of its workPharmacology: 1 fractional works · 0.8% of its workNeuroscience: 1 fractional works · 1.9% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.5% of its workNeurology: 0 fractional works · 0.5% of its workEndocrine and Autonomic Systems: 0 fractional works · 0.4% of its workBehavioral Neuroscience: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 0.9% of its workFood Science: 0 fractional works · 0.4% of its workPlant Science: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workSocial Sciences: 2 fractional works · 2.2% of its workDecision Sciences: 1 fractional works · 1.0% of its workStatistics, Probability and Uncertainty: 0 fractional works · 0.5% of its workManagement Science and Operations Research: 0 fractional works · 0.5% of its workEconomics, Econometrics and Finance: 1 fractional works · 0.9% of its workEconomics and Econometrics: 1 fractional works · 0.9% of its workSocial Sciences: 0 fractional works · 0.2% of its workHealth: 0 fractional works · 0.2% of its workPsychology: 0 fractional works · 0.1% of its workALL ITS WORKOnoPharmaceutical…72fractional works, 2022-now
Life Sciences23%Physical Sciences24%Health Sciences50%Social Sciences2%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 22 fields, with their numbers
    1. Medicine3548.4%
    2. Health Professions11.4%
    3. Nursing00.3%
    4. Veterinary00.2%
    1. Chemistry79.4%
    2. Engineering67.8%
    3. Computer Science22.9%
    4. Mathematics11.7%
    5. Materials Science11.1%
    6. Chemical Engineering00.6%
    7. Environmental Science00.3%
    8. Earth and Planetary Sciences00.2%
    9. Physics and Astronomy00.1%
    1. Biochemistry, Genetics and Molecular Biology1014.3%
    2. Immunology and Microbiology23.5%
    3. Pharmacology, Toxicology and Pharmaceutics22.9%
    4. Neuroscience11.9%
    5. Agricultural and Biological Sciences10.9%
    1. Decision Sciences11.0%
    2. Economics, Econometrics and Finance10.9%
    3. Social Sciences00.2%
    4. Psychology00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.18× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 2.69× its world share, 10 worksBiochemistry, Geneti…Immunology and Microbiology: 3.44× its world share, 2 worksImmunology and Micro…Neuroscience: 1.15× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 8.24× its world share, 2 worksPharmacology, Toxico…Chemical Engineering: 1.77× its world share, 0 worksChemical EngineeringChemistry: 6.00× its world share, 7 worksChemistryComputer Science: 0.37× its world share, 2 worksComputer ScienceEarth and Planetary Sciences: 0.12× its world share, 0 worksEarth and Planetary …Engineering: 0.52× its world share, 6 worksEngineeringEnvironmental Science: 0.06× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.30× its world share, 1 worksMaterials ScienceMathematics: 1.48× its world share, 1 worksMathematicsPhysics and Astronomy: 0.04× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.52× its world share, 1 worksHealth ProfessionsMedicine: 2.52× its world share, 35 worksMedicineNursing: 0.66× its world share, 0 worksNursingVeterinary: 1.11× its world share, 0 worksVeterinaryDecision Sciences: 1.04× its world share, 1 worksDecision SciencesEconomics, Econometrics and Finance: 0.41× its world share, 1 worksEconomics, Econometr…Psychology: 0.02× its world share, 0 worksPsychologySocial Sciences: 0.02× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 8.2×. Every wedge is a field page.

All 22 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics8.24×2 works
  2. Chemistry6.00×7 works
  3. Immunology and Microbiology3.44×2 works
  4. Biochemistry, Genetics and Molecular Biology2.69×10 works
  5. Medicine2.52×35 works
  6. Chemical Engineering1.77×0 works
  7. Mathematics1.48×1 works
  8. Neuroscience1.15×1 works
  9. Veterinary1.11×0 works
  10. Decision Sciences1.04×1 works
  11. Nursing0.66×0 works
  12. Engineering0.52×6 works
  13. Health Professions0.52×1 works
  14. Economics, Econometrics and Finance0.41×1 works
  15. Computer Science0.37×2 works
  16. Materials Science0.30×1 works
  17. Agricultural and Biological Sciences0.18×1 works
  18. Earth and Planetary Sciences0.12×0 works
  19. Environmental Science0.06×0 works
  20. Physics and Astronomy0.04×0 works
  21. Psychology0.02×0 works
  22. Social Sciences0.02×0 works

Who are the top researchers at Ono Pharmaceutical (Japan)?

Ranked on the quality score, Shinji Nakade, Tsumoru Miyamoto and Yoshikazu Takaoka lead among researchers whose main affiliation is Ono Pharmaceutical (Japan).

  1. 1 Shinji Nakade Japan · #959,923 worldwide 3.6k citations · 46 works
  2. 2 Tsumoru Miyamoto Japan · #1,276,204 worldwide 2.1k citations · 22 works
  3. 3 Yoshikazu Takaoka Japan · #1,355,758 worldwide 1.7k citations · 35 works
  4. 4 Daikichi Fukushima Japan · #1,447,027 worldwide 2.3k citations · 43 works
  5. 5 Hirotaka Mizuno Japan · #1,621,726 worldwide 1.2k citations · 21 works
  6. 6 Yoshiya Aze Japan · #1,877,599 worldwide 3.9k citations · 36 works
  7. 7 Tai Shiraishi Japan · #1,945,435 worldwide 888 citations · 18 works
  8. 8 Hiroji Oida Japan · #2,023,895 worldwide 2.6k citations · 33 works
  9. 9 Hisao Tajima Japan · #2,283,558 worldwide 1.2k citations · 15 works
  10. 10 Yoshiyuki Yamaura Japan · #2,607,687 worldwide 1.1k citations · 45 works
All ranked researchers at Ono Pharmaceutical (Japan)

What are the most cited papers from Ono Pharmaceutical (Japan)?

The most cited paper from Ono Pharmaceutical (Japan) is "Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial" (Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al., 2019), with 1,262 citations. Next come "2APB, 2-Aminoethoxydiphenyl Borate, a Membrane-Penetrable Modulator of Ins(1,4,5)P3-Induced Ca2+ Release" (918) and "Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial" (808).

Most cited papers
#PaperReleasedCitations
1 Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology Open access 30 Sep 2019 1,262
2 2APB, 2-Aminoethoxydiphenyl Borate, a Membrane-Penetrable Modulator of Ins(1,4,5)P3-Induced Ca2+ Release Takayuki Maruyama, Toshiya Kanaji, Shinji Nakade et al. · The Journal of Biochemistry Sep 1997 918
3 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang et al. · The Lancet Oncology Open access 11 Jan 2022 808
4 Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Tatsunori Murata, Fumitaka Ushikubi, Toshiyuki Matsuoka et al. · Nature 14 Aug 1997 785
5 Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo Hanako Ohashi Ikeda, Masahiro Yamaguchi, Satoshi Sugai et al. · Nature Genetics Jun 1996 551
All 60 most cited papers, with filters and sorting

Which keywords describe research at Ono Pharmaceutical (Japan)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Inflammation, Immunotherapy, Tumor Microenvironment, Lymphoma, Chemotherapy, Cancer Immunotherapy, Prognostic Factors and Rituximab.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Inflammation6▲ 4.0×31 topics
  2. Immunotherapy4▲ 8.0×11 topics
  3. Tumor Microenvironment4▲ 11×6 topics
  4. Epidemiology4▲ 1.22×23 topics
  5. Cancer3▲ 3.3×17 topics
  6. Chemotherapy3▲ 5.7×13 topics
  7. Lymphoma3▲ 24×2 topics
  8. Cancer Immunotherapy2▲ 23×3 topics
  9. Prognostic Factors2▲ 8.0×7 topics
  10. Rituximab2▲ 24×3 topics
  11. Immune Checkpoint Blockade2▲ 28×1 topic
  12. PD-1 and PD-L12▲ 28×1 topic
  13. Drug Discovery2▲ 14×3 topics
  14. Aging2▲ 5.0×3 topics
  15. Therapeutic Targets2▲ 18×4 topics
  16. CAR T Cells2▲ 37×1 topic
  17. Chimeric Antigen Receptor2▲ 37×1 topic
  18. Tumor Regression2▲ 24×2 topics
  19. Heterocycles2▲ 25×3 topics
  20. Metal-Catalyzed Reactions2▲ 38×2 topics
  21. Chronic Lymphocytic Leukemia2▲ 53×1 topic
  22. Genomic Aberrations2▲ 53×1 topic
  23. Muscle Mass2▲ 20×2 topics
  24. Prognosis2▲ 6.6×3 topics
  25. Cancer Cachexia2▲ 23×1 topic
  26. Sarcopenia2▲ 23×1 topic
  27. Cardiovascular Risk1▲ 6.3×4 topics
  28. Cell Culture1▲ 17×3 topics
  29. Protein-Protein Interactions1▲ 43×2 topics
  30. Enantioselective Synthesis1▲ 30×3 topics
  31. Foldamers1▲ 61×1 topic
  32. Medicinal Chemistry1▲ 6.6×5 topics
  33. Neoadjuvant Therapy1▲ 7.8×4 topics
  34. Peptide Synthesis1▲ 61×1 topic
  35. Survival Analysis1▲ 6.4×5 topics
  36. Transition Metal Catalysis1▲ 22×2 topics
  37. Glycosylation1▲ 15×3 topics
  38. PET Imaging1▲ 10×4 topics
  39. Colorectal Cancer1▲ 20×2 topics
  40. Monoclonal Antibodies1▲ 17×3 topics

Which research topics does Ono Pharmaceutical (Japan) publish most on?

By volume in 2022-now: Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research and Nutrition and Health in Aging.

Cancer Immunotherapy and Biomarkers: 2 fractional worksCAR-T cell therapy research: 2 fractional worksChronic Lymphocytic Leuk…2Chronic Lymphocytic Leukemia Research: 2 fractional worksNutrition and Health in …2Nutrition and Health in Aging: 2 fractional worksChemical Synthesis and Analysis: 1 fractional worksDrug Solubulity and Delivery Systems: 1 fractional worksCatalytic C–H Functional…1Catalytic C–H Functionalization Methods: 1 fractional worksInflammatory mediators and NSAID effects: 1 fractional worksMachine Fault Diagnosis Techniques: 1 fractional worksImmune Cell Function and Interaction: 1 fractional works
OncologyGeneticsPhysiologyMolecular Biology5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Cancer Immunotherapy and Biomarkers Oncology 2 works
  2. 2 CAR-T cell therapy research Oncology 2 works
  3. 3 Chronic Lymphocytic Leukemia Research Genetics 2 works
  4. 4 Nutrition and Health in Aging Physiology 2 works
  5. 5 Chemical Synthesis and Analysis Molecular Biology 1 works
  6. 6 Drug Solubulity and Delivery Systems Pharmaceutical Science 1 works
  7. 7 Catalytic C–H Functionalization Methods Organic Chemistry 1 works
  8. 8 Inflammatory mediators and NSAID effects Pharmacology 1 works
  9. 9 Machine Fault Diagnosis Techniques Control and Systems Engineering 1 works
  10. 10 Immune Cell Function and Interaction Immunology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available39.2%not open60.8%

World: 40% of research is openly available.

with international co-authors17.7%domestic only82.3%

World: 18% is written across borders.

How has Ono Pharmaceutical (Japan)'s research output changed?

Output in 2022-2025 was 31% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Ono Pharmaceutical (Japan) as a percentage of every work published that year, 0.00036% in 2024.

still counting0.0020%0.0040%Ono Pharmaceutical (Japan)0.00028% in 202519801990200020102020

Fractional works of Ono Pharmaceutical (Japan) over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year, against all institutions in the same year.

5%10%15%all institutions10.0% in 2020Ono Pharmaceutical (Japan)4.1% in 2020200020102020

Of each year's output, the share that reached the world's 10% most cited for its field and year. Peak 14.8% in 1992.

Other research institutions in Osaka

All research institutions in Osaka

Share Ono Pharmaceutical (Japan)'s ranking

Ono Pharmaceutical (Japan) on Science Explorer

A card with Ono Pharmaceutical (Japan)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Ono Pharmaceutical (Japan). Posts are plain text and can be reported.